Nasdaq
$11.20▲ 0.63%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $791.0MShares out 70.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 3d agoPre-market26.10.22 20:066-KKey event#●●●#●●●#●●●
Pharming Group N.V.Bullish
Pharming Group announced that its total revenue for the third quarter of 2026 increased by 21% year-on-year to approximately US$117.6 million. Based on strong performance from RUCONEST and Joenja, the company tightened its 2026 total revenue guidance to US$380 million–US$390 million and lowered its operating expense guidance.…more
$11.20+0.63%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14Pre-market26.10.14 19:036-KKey event
Pharming Group N.V.
Pharming Group announced positive topline data from its Phase II trial of leniolisib in patients with genetically identifiable primary immunodeficiencies (PIDs). The study of 13 participants demonstrated efficacy in addressing immune dysregulation, including reductions in spleen volume and improvements in lung function, with all participants enrolling in a three-year extension study.…more
$11.20+0.63%vs prev closeView filingShare - 9.29Pre-market26.09.29 19:406-KKey event
Pharming Group N.V.
Pharming Group announced that CEO Fabrice Chouraqui has stepped down effective immediately due to a misalignment on the company's strategic direction. To ensure leadership continuity, Chief Commercial Officer Leverne Marsh and Chief Financial Officer Kenneth Lynard have been appointed as interim co-CEOs.…more
$11.20+0.63%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoOvernight26.10.22 14:27#●●●#●●●
Pharming Reports 21% Q3 Revenue Growth and Tightens 2026 Guidance
Pharming's Q3 revenue rose 21% year-over-year to $117.6 million, while operating expenses remained flat. The company narrowed its 2026 full-year revenue guidance to a range of $380 million to $390 million.…more
$11.20+0.63%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 3d agoOvernight26.10.22 14:00
●●●●●●●● ●●●●● ●●●●●●
Pharming Group reported third-quarter revenues of $117.6 million, a 21% year-over-year increase that surpassed market expectations. The company also tightened its full-year 2026 revenue and operating expense guidance based on strong product performance and efficient cost management.…more
$11.20+0.63%vs prev close - 10.14Overnight26.10.14 15:00
●●●●●●●● ●●●●● ●●●●●●
Pharming announced positive Phase II topline data for leniolisib, demonstrating improvements in immune dysregulation markers and a favorable safety profile. While these results support potential label expansion, the data remains in the clinical trial stage.…more
$11.20+0.63%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report